Eli Lilly Treatment For Crohn's Tops Placebo In Latest Study, Makes Plans For 2024

Eli Lilly And Co LLY plans to submit a marketing application for a drug that treats Crohn's disease to the Food and Drug Administration (FDA) in 2024.

The company recently announced that mirikizumab met the co-primary and all major secondary endpoints compared to the placebo in VIVID-1 Phase 3 study of mirikizumab for moderately to severely active Crohn's disease

The trial included mirikizumab, placebo, and active control Johnson & Johnson's JNJ Stelara (ustekinumab) arms.

In the VIVID-1 study, all patients in the active treatment arms from the 12-week induction period continued with their original therapy into the maintenance portion of the study up to Week 52.

Also Read: FDA Declines To Approve Eli Lilly's Eczema Drug

Placebo patients who did not achieve clinical response at Week 12 (nonresponders) were switched to blinded mirikizumab treatment.

In the mirikizumab arm, a statistically higher proportion achieved clinical response at Week 12 and clinical remission at Week 52 compared to placebo (45.4% versus 19.6%).

In the mirikizumab arm, a statistically higher proportion achieved clinical response at Week 12 and endoscopic response at Week 52 compared to placebo (38% versus 9%).

Notably, of the patients who received mirikizumab, 54.1% achieved clinical remission at Week 52 compared to 19.6% of patients who received a placebo. 

In addition, for the endpoint of clinical remission, mirikizumab demonstrated non-inferiority versus ustekinumab (non-inferiority margin of 10%). 

For the endpoint of endoscopic response at Week 52, mirikizumab did not achieve superiority to ustekinumab, although results with mirikizumab were numerically higher, particularly in the non-multiplicity-controlled bio-failed population.

Price Action: LLY shares are up 0.31% at $607.13 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!